Topics

MorphoSys AG: MOR106 Clinical Development in Atopic Dermatitis Stopped for Futility

17:20 EDT 28 Oct 2019 | FinanzNachrichten

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 28, 2019 / MorphoSys AG (FSE:MOR; Prime Standard Segment, TecDAX; NASDAQ:MOR) today announced the end of the clinical development program of MOR106 in...

Original Article: MorphoSys AG: MOR106 Clinical Development in Atopic Dermatitis Stopped for Futility

NEXT ARTICLE

More From BioPortfolio on "MorphoSys AG: MOR106 Clinical Development in Atopic Dermatitis Stopped for Futility"

Quick Search